For a 60‑year‑old female resident of a long‑term care facility currently taking buspirone 5 mg twice daily, hydroxyzine 25 mg nightly, and quetiapine 100 mg nightly after duloxetine was discontinued, how should her anxiety/depression medication regimen be optimized?

Optimize This Polypharmacy Regimen by Reinstating Duloxetine

This patient's anxiety and depression medications should be consolidated by restarting duloxetine 60 mg daily, then tapering and discontinuing the quetiapine 100 mg (which was inappropriately substituted for an antidepressant), while continuing buspirone and using hydroxyzine only as needed for breakthrough anxiety.

---

Why Duloxetine Was Likely Discontinued and Why It Should Be Restarted

The Hospital Made an Error

• Duloxetine (Cymbalta) is FDA-approved for major depressive disorder and generalized anxiety disorder, making it the cornerstone medication for this 60-year-old woman with both conditions 1.
• Quetiapine 100 mg at bedtime is not an appropriate substitute for an antidepressant—it is an atypical antipsychotic FDA-approved for schizophrenia, bipolar mania, and bipolar depression, not for primary anxiety or unipolar depression in the absence of psychotic features 2.
• The hospital likely discontinued duloxetine due to concerns about drug interactions, cost, formulary restrictions, or misinterpretation of her symptoms as requiring antipsychotic coverage, but none of these justify replacing a proven antidepressant with an antipsychotic in a patient without psychosis 1, 2.

Evidence Supporting Duloxetine for Anxiety and Depression

• Duloxetine at 60 mg daily (the recommended starting and therapeutic dose) demonstrates rapid relief of anxiety symptoms associated with depression, with remission rates of 43–57% across controlled trials 3.
• Duloxetine's dual serotonin-norepinephrine reuptake inhibition treats the broad spectrum of depressive symptoms—including mood, anxiety, and painful physical symptoms—more comprehensively than SSRIs alone 3.
• In head-to-head comparisons, duloxetine 60–120 mg daily was superior to placebo on anxiety measures (Hamilton Anxiety Scale, HAMD anxiety/somatization subfactor) at the last study visit and across all study visits 3.

---

Step-by-Step Medication Optimization Plan

Step 1: Reinstate Duloxetine Immediately

• Restart duloxetine 30 mg once daily for 1 week to allow the patient to readjust to the medication, then increase to 60 mg once daily (the recommended therapeutic dose) 1.
• If she was previously stable on a higher dose (e.g., 60 mg twice daily or 120 mg daily), titrate back to that dose over 2–3 weeks, though doses above 60 mg daily confer no additional benefit for most patients 1.
• Administer duloxetine with or without meals; instruct the patient to swallow capsules whole and not to chew, crush, or open them 1.

Step 2: Taper and Discontinue Quetiapine

• Begin tapering quetiapine 100 mg at bedtime once duloxetine reaches 60 mg daily (approximately 1–2 weeks after restarting duloxetine) 2.
• Reduce quetiapine by 25 mg every 3–7 days (e.g., 100 mg → 75 mg → 50 mg → 25 mg → discontinue) to minimize withdrawal symptoms such as insomnia, nausea, and rebound anxiety 2.
• Quetiapine is not indicated for this patient because she has no documented psychotic features, bipolar disorder, or treatment-resistant depression requiring antipsychotic augmentation 2.
• Continuing quetiapine unnecessarily exposes her to metabolic side effects (weight gain, hyperglycemia, dyslipidemia), extrapyramidal symptoms, and sedation 4, 2.

Step 3: Continue Buspirone and Optimize Dosing

• Maintain buspirone 5 mg twice daily as adjunctive anxiolytic therapy 5, 6.
• Buspirone is effective for generalized anxiety disorder and produces significant improvement in anxiety symptoms as early as the first week of treatment, with progressive improvement over subsequent weeks 6, 7.
• If anxiety remains inadequately controlled after 2–4 weeks on duloxetine 60 mg plus buspirone 10 mg daily, increase buspirone to 15 mg daily (5 mg three times daily), then to a maximum of 60 mg daily in divided doses if needed 5, 6.
• Buspirone is safe and well tolerated at doses up to 90 mg daily, though most patients respond to 20–30 mg daily 5.

Step 4: Use Hydroxyzine Only as Needed

• Reduce hydroxyzine 25 mg at bedtime to as-needed use for breakthrough anxiety or insomnia once duloxetine and buspirone are optimized 7.
• Hydroxyzine is effective for generalized anxiety disorder and superior to placebo on the Hamilton Anxiety Scale, but chronic nightly use is unnecessary when a patient is on adequate doses of duloxetine and buspirone 7.
• Hydroxyzine 12.5–25 mg can be used up to three times daily as needed, but avoid daily scheduled dosing to minimize anticholinergic side effects (dry mouth, constipation, urinary retention) and sedation in a 60-year-old woman 7.

---

Monitoring and Follow-Up

Week 1–2: Reinstate Duloxetine and Monitor Tolerability

• Assess for nausea, headache, dizziness, and insomnia (common early side effects of duloxetine) 1.
• Monitor blood pressure, as duloxetine can cause modest elevations 8.
• Evaluate for suicidal ideation, especially in the first 1–2 months after restarting an antidepressant 8.

Week 2–4: Increase Duloxetine to 60 mg and Begin Quetiapine Taper

• Confirm the patient tolerates duloxetine 60 mg daily before starting the quetiapine taper 1.
• Monitor for withdrawal symptoms during quetiapine taper (insomnia, nausea, rebound anxiety) and slow the taper if needed 2.

Week 4–8: Assess Response and Optimize Buspirone

• Use standardized rating scales (Hamilton Anxiety Scale, PHQ-9) to objectively track anxiety and depression symptoms 8.
• If anxiety remains inadequately controlled, increase buspirone to 15–30 mg daily in divided doses 5, 6.
• Allow 6–8 weeks at duloxetine 60 mg daily before declaring treatment failure, as full antidepressant response may take this long 8.

Week 8–12: Reassess and Consider Augmentation if Needed

• If the patient has not achieved remission after 8 weeks on duloxetine 60 mg plus buspirone 15–30 mg daily, consider increasing duloxetine to 120 mg daily (though evidence for additional benefit is limited) 1.
• Alternatively, add cognitive-behavioral therapy (CBT), which demonstrates superior efficacy when combined with medication compared to medication alone 8.

---

Critical Safety Considerations

Avoid Combining Duloxetine with Other Serotonergic Agents

• Do not combine duloxetine with MAOIs, SSRIs, SNRIs, triptans, tramadol, or St. John's wort due to serotonin syndrome risk 8.
• Serotonin syndrome manifests as mental status changes (confusion, agitation), neuromuscular hyperactivity (tremor, clonus), and autonomic hyperactivity (hypertension, tachycardia, diaphoresis) and requires immediate hospitalization if severe 8.

Monitor for Suicidal Ideation

• Assess suicidal thoughts at every visit during the first 1–2 months after restarting duloxetine, as suicide risk is greatest during this period 8.

Adjust Duloxetine Dose in Renal or Hepatic Impairment

• If the patient has moderate to severe renal impairment (eGFR < 90 mL/min), reduce the duloxetine dose by 50% (e.g., 30 mg daily instead of 60 mg daily) 8.
• If she has moderate to severe hepatic impairment, the maximum dose is 150 mg every other day 8.

---

Common Pitfalls to Avoid

Do Not Continue Quetiapine Long-Term Without a Clear Indication

• Quetiapine is not FDA-approved for primary anxiety or unipolar depression and exposes the patient to unnecessary metabolic and neurologic risks 2.
• The only justification for continuing quetiapine would be documented psychotic features, bipolar disorder, or treatment-resistant depression requiring antipsychotic augmentation—none of which are described in this case 4, 2.

Do Not Switch Antidepressants Before Allowing Adequate Trial Duration

• Duloxetine requires 6–8 weeks at 60 mg daily to assess full efficacy; premature switching delays recovery 8.

Do Not Exceed Duloxetine 120 mg Daily

• Doses above 120 mg daily are not FDA-approved and confer no additional benefit while increasing side effects 1.

Do Not Use Hydroxyzine Chronically in Older Adults

• Hydroxyzine has anticholinergic properties and can cause sedation, falls, and cognitive impairment in older adults 7.
• Reserve hydroxyzine for as-needed use only 7.

---

Summary Algorithm

1. Restart duloxetine 30 mg daily × 1 week, then increase to 60 mg daily 1.
2. Once duloxetine reaches 60 mg daily, taper quetiapine by 25 mg every 3–7 days until discontinued 2.
3. Continue buspirone 5 mg twice daily; increase to 15–30 mg daily if anxiety persists after 4 weeks 5, 6.
4. Reduce hydroxyzine 25 mg at bedtime to as-needed use for breakthrough anxiety 7.
5. Reassess at 6–8 weeks; if no remission, increase duloxetine to 120 mg daily or add CBT 8, 1.
6. Monitor for suicidal ideation, serotonin syndrome, and withdrawal symptoms throughout 8.